European approval granted for Trajenta® (linagliptin) tablets as add-on therapy to insulin in adults with Type 2 Diabetes

European approval granted for Trajenta® (linagliptin) tablets as add-on therapy to insulin in adults with Type 2 Diabetes

BusinessWire · Oct. 26, 2012

Boehringer Ingelheim and Eli Lilly and Companytoday announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes.

"We are delighted that approval has been granted for the use of linagliptin as an add-on to insulin in adults with Type 2 Diabetes," said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim, "This expanded indication shows that linagliptin is an effective treatment for patients at various stages of Type 2 Diabetes."

The approval means linagliptin is now indicated for use in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

The approval is based on data from a number of clinical studies, including efficacy data from a Phase III trial of at least 52 weeks duration demonstrating the efficacy and safety profile of linagliptin in combination with basal insulin (primary endpoint: efficacy after 24 weeks). The trial results showed that after 24 weeks, adding linagliptin to insulin produced better glucose control than insulin alone, without an additional risk of hypoglycaemia.1

The US FDA approved linagliptin for use as add on to insulin in adults with Type 2 Diabetes in August 2012.

~ends~

Please click on the link below for 'Notes to Editors' and 'References':

http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/26_october_2012_linagliptin.html

###

Contacts

Boehringer Ingelheim GmbH
Ute E Schmidt
Email: [email protected]
Phone: +49 (6132) 77-97296
or
Lilly Diabetes
Tammy Hull
Communications Manager
Email: [email protected]
Phone: +1 (317) 651-9116

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.